Profile data is unavailable for this security.
About the company
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
- Revenue in USD (TTM)0.00
- Net income in USD-36.32m
- Incorporated2007
- Employees91.00
- LocationNeurogene Inc535 W 24Th Street, 5Th FloorNEW YORK 10011United StatesUSA
- Phone+1 (206) 732-2133
- Fax+1 (302) 655-5049
- Websitehttps://www.neurogene.com/
Mergers & acquisitions
Acquired company | NGNE:NMQ since announced | Transaction value |
---|---|---|
Neurogene Inc | 75.68% | 200.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tourmaline Bio Inc | 0.00 | -42.12m | 404.45m | 44.00 | -- | 1.56 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Biomea Fusion Inc | 0.00 | -127.27m | 411.21m | 110.00 | -- | 3.04 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
Replimune Group Inc | 0.00 | -209.96m | 413.14m | 284.00 | -- | 0.9801 | -- | -- | -3.16 | -3.16 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -34.66 | -26.12 | -36.63 | -27.31 | -- | -- | -- | -- | -- | -- | 0.1436 | -- | -- | -- | -47.65 | -- | 75.59 | -- |
Contineum Therapeutics Inc | 50.00m | 22.72m | 419.12m | 31.00 | 17.72 | -- | 18.26 | 8.38 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Neurogene Inc | 0.00 | -36.32m | 427.27m | 91.00 | -- | 2.29 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
Ocugen Inc | 6.04m | -63.08m | 429.74m | 65.00 | -- | 10.56 | -- | 71.20 | -0.2616 | -0.2616 | 0.0247 | 0.1581 | 0.0697 | -- | -- | 92,861.54 | -72.85 | -83.56 | -91.66 | -97.79 | -- | -- | -1,045.03 | -2,921.94 | -- | -- | 0.0646 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
PepGen Inc | 0.00 | -78.63m | 432.09m | 64.00 | -- | 2.93 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
iTeos Therapeutics Inc | 12.60m | -112.64m | 438.42m | 157.00 | -- | 0.7595 | -- | 34.81 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
ADC Therapeutics SA | 68.62m | -227.23m | 439.58m | 273.00 | -- | -- | -- | 6.41 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
Cibus Inc | 1.82m | -267.63m | 442.06m | 183.00 | -- | 1.25 | -- | 243.29 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
Heron Therapeutics Inc | 132.10m | -80.95m | 442.87m | 126.00 | -- | -- | -- | 3.35 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
Fate Therapeutics Inc | 63.53m | -160.93m | 443.89m | 181.00 | -- | 1.04 | -- | 6.99 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Nkarta Inc | 0.00 | -117.50m | 443.95m | 150.00 | -- | 1.13 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Tscan Therapeutics Inc | 21.05m | -89.22m | 445.69m | 154.00 | -- | 2.47 | -- | 21.17 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Revance Therapeutics Inc | 234.04m | -323.99m | 447.09m | 534.00 | -- | -- | -- | 1.91 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Editas Medicine Inc | 69.41m | -166.13m | 457.23m | 265.00 | -- | 1.55 | -- | 6.59 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Dec 2023 | 1.27m | 9.89% |
Great Point Partners LLCas of 31 Dec 2023 | 994.23k | 7.74% |
Redmile Group LLCas of 31 Dec 2023 | 946.90k | 7.37% |
Janus Henderson Investors US LLCas of 31 Dec 2023 | 841.69k | 6.55% |
Cormorant Asset Management LPas of 31 Dec 2023 | 746.18k | 5.81% |
ArrowMark Colorado Holdings LLCas of 31 Dec 2023 | 525.53k | 4.09% |
Casdin Capital LLCas of 31 Dec 2023 | 524.62k | 4.08% |
Avidity Partners Management LPas of 31 Dec 2023 | 466.24k | 3.63% |
Baker Bros. Advisors LPas of 31 Dec 2023 | 453.52k | 3.53% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 336.77k | 2.62% |